11 November 2020
Visiongain has published a new report on Addiction Treatment Market Report 2021-2031: Forecasts by Type (Tobacco/ Nicotine, Alcohol dependence, Marijuana, Synthetic Cannabinoids, Prescription and Over-the-Counter Medications, Drug abuse and Others), By Treatment Type (Nicotine Replacement Therapy, Psychological Therapy, Counseling and Behavioral Therapies, Rehabilitation programs, Psychotherapy and Others), By Drug Type (Approved-Drugs and Off-label Drugs), By Product Type (Patch, Gum, Pills, Lozenge, Spray and Others), By Route of Administration (Oral, Inhalation and Injectable), By End-User (Hospitals, Homecare, Specialty Clinics, Rehabilitation Treatment Centers and Others), By Distribution Channel (Hospital Pharmacy, Retail pharmacy, Ecommerce and Others). PLUS Profiles of Leading Manufacturing Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios.
Global Addiction Treatment market was valued at US$ xx Million in 2020 and is projected to reach a market value of US$ xx Million by 2031. North America dominated the global Addiction Treatment market and is projected to witness a CAGR of XX% during the first half of the forecast period i.e. 2021 to 2031.
COVID-19 Impact on Addiction Treatment Market
COVID-19 impact through different recovery models such as V-shaped, U-shaped, W-shaped, and L-shaped; has been taken into consideration while estimating and forecasting the Addiction Treatment market. Different recovery scenarios are also included in the report for all the segments and regions/nation. The recovery scenarios based on which market has been forecasted and analysed herein the report are mentioned below:
Increasing Consumptions of Tobacco Products
Consumptions of tobacco are significantly increasing and expected to continuously rise over the forecast period. The increase in the consumptions of tobacco creates a huge demand for the addiction treatment products giving an opportunity to the manufacturer to come up with innovative and cost effective product to cater the high demand. According to U.S. Department of Health & Human Services, 5.6 million of Americans younger than 18 will die early from a smoking-related illness.
Government Initiative and Awareness Program
Governments in various developed and developing nations are increasing their initiatives to increase awareness regarding repercussions associated with the consumption of tobacco/ nicotine, alcohol dependence, marijuana, synthetic cannabinoids, drug abuse consumption. Further, Governments and private authority across the developed & developing countries are focusing to increase the number of addiction treatment centres with new approval of addiction treatment drugs. For Instance: U.S. Department of Health & Human Services has launched tobacco control programs by featuring national and local campaigns and events, linking to state and community resources, producing guidelines, and compiling data.
Technological Advancements and the modernization in addiction treatment
Researchers and manufacturers from all over the world are increasing research and development activities for new advancements in the addiction treatment especially in tobacco/ nicotine, alcohol dependence, marijuana, synthetic cannabinoids, drug abuse helps to increase adoption of novel technologies in the addiction treatment arena. New research and development activities are expected to create competitive advantages by increasing advancements in the product which will create new opportunities in the market.
Top companies (Cipla Ltd., GlaxoSmithKline plc, Pfizer Inc., Novartis AG, Sanofi, Dr. Reddy’s Laboratories Ltd, Teva Pharmaceutical Industries Ltd., Mylan N.V. and Axsome Therapeutics, Inc.) constitute more than XX% share of the global addiction treatment market. Other company's profile in the report include: – Mallinckrodt Plc., Hikma Pharmaceuticals plc, Orexo AB, Indivior PLC, Hager Biosciences, LLC, ADDEX THERAPEUTICS, Omeros Corporation, Sosei Group Corporation, CV Sciences, Inc., Astraea Therapeutics LLC, Altria Group, Inc., Johnson & Johnson Services, Inc., Novartis AG and Sanofi among others. Some of the key developments are listed below:
• In 2019, Omeros Corporation has published positive results from OMS527 program Phase 1 study, a inhibitors for the treatment of addictions. Through this development company will widened their market focused product portfolio.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
29 July 2021
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
21 July 2021
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
20 July 2021
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.